1. Generic drug user fees: application review times declined, but FDA should develop a plan for administering its unobligated user fees : report to the Chairman, Committee on Health, Education, Labor, and Pensions, U.S. Senate Publication: Washington, D.C. : U.S. Government Accountability Office, May 2017 Subject(s): Drugs, Generic -- economicsDrugs, Investigational -- economicsInvestigational New Drug Application -- economicsDrug Approval -- economicsHumansUnited StatesUnited States. Food and Drug Administration.
